On the morning of October 27, 2025, the Overseas Project Roadshow of the 10th China BioMed Innovation and Investment Conference (CBIIC) was successfully held in Nanjing.

The overseas project roadshow was moderated by Ms. Sanorita LI, Head of Heath Industry China, Business Finland. As an important milestone marking the 10th anniversary of CBIIC, it fully demonstrates the vigorous development and accelerated internationalization of China’s innovative pharmaceutical industry. Aligning closely with the conference theme, this overseas project roadshow aims to connect global innovative forces, promote in-depth cooperation between Chinese and foreign enterprises, and highlights the high dependence and value of international cooperation for the development of the pharmaceutical industry.

Moderator: Ms. Sanorita LI

Innovative Insights and Industrial Opportunities from a Global Perspective

Mr. Kuno Gschwend, Deputy Head and Chief Investment Promotion Officer of the Swiss Business Hub China, Embassy of Switzerland in China delivered a keynote speech entitled Switzerland: The Life Sciences Hotspot in Europe. He noted that, as a leading European life sciences hub, Switzerland offers an enabling environment for life sciences enterprises thanks to its political stability, high-quality education, open business climate and competitive tax regime. Consistently ranking first in the Global Innovation Index, Switzerland has built world-class industrial clusters in pharmaceuticals, biotechnology and medical technology, attracting global leaders including Roche and Novartis to establish a presence. Mr. Gschwend specifically highlighted that with its convenient geographical location and well-established free trade network, Switzerland has become the preferred destination for enterprises to set up European headquarters and R&D centers. A growing number of Chinese companies, including BeOne Medicines, have also achieved international growth in Switzerland.

Mr. Kuno Gschwend, Deputy Head and Chief Investment Promotion Officer of the Swiss Business Hub China, Embassy of Switzerland in China, delivered keynote speech

Project 1

QuantModE Co., Ltd.: First-Strike Screening with Epitranscriptomics & AI: Stop Colorectal Cancer Before It Exists

Mr. XIE Wenxuan, CEO, introduced that the project “EpiLumenix” is based on liquid biopsy technology. By detecting multiple chemical modification profiles of cell-free RNA from host and gut microbiota, combined with an AI model, it achieves an accurate recognition rate of 94% for early screening of colorectal cancer. The technology offers advantages including non-invasiveness and sample stability. The company plans to promote a B2B2C business model through cooperation with private hospitals, and expand its application to early screening of multiple cancer types such as liver cancer, with the goal of building an early detection and prevention system for multiple cancers.

Project 2: WAT Medical Enterprise Ltd: Based on Edge Al and Targeted Neural Modulation Techniques

Ray JI, CEO, introduced that the device utilizes AI Edge Al and Targeted Neural Modulation Techniques to achieve personalized blood pressure regulation through precise stimulation of peripheral nerves. Clinical validation has demonstrated significant blood pressure reduction and decreased medication dependence. Leveraging its R&D strengths in both China and Canada, WAT Medical is advancing clinical validation and market access, providing innovative solutions for the prevention and treatment of hypertension worldwide.

Project3: Hong Kong OPbio Technology Limited: CytoSpark® Microfluidic High-throughput Screening System

Ms. WAN Wei, Vice President, introduced that the company has built a high-throughput system covering antibody screening and functional verification based on autonomous microfluidic technology, with a single B-cell screening throughput of up to one million. Its products have been widely used in antibody drug discovery and synthetic biology research, and the company has established partnerships with a number of multinational pharmaceutical companies. It is committed to becoming a core technology platform for life science R&D in the AI era.

Project 4: Orum Therapeutics: TPD² Approach - Dual-precision Targeted Protein Degradation

Mr. Sungjoo LEE, Chief Executive Officer, introduced that the company has achieved precise degradation of intracellular undruggable targets through an innovative “degrader-antibody conjugate” mechanism. The flagship project ORM-6151 has been acquired by BMS and advanced to Phase I clinical development. The company has established strategic collaborations with Vertex, BMS and other partners, demonstrating the broad application potential of its technology in oncology and gene therapy.

Project 5: NZeno Biontech (HK) Limited: Leading A New Era in Xenotransplantation and Regenerative Medicine

Ms. HUANG Wenjing, Chief Executive Officer, introduced that NZeno Biontech holds the global commercialization rights to the Auckland Island pig.This pig strain is PERV-C negative, with organ size matching that of humans, making it an ideal source of organ donors. The company is systematically advancing IND applications for kidney and heart xenotransplantation products, with the goal of commercialization in 2029–2030. It is also developing derivative applications such as cell therapy and biomaterials.

Project 6: DeepSense Bio Information Co., Ltd.: Computational Strategy-driven Drug Design

Mr. LIU Tianyue, Chief Executive Officer, stated that the company’s platform significantly improves molecular design efficiency through data integration and customized algorithms, and has been successfully applied to the development of FLT3 covalent inhibitors. The company adopts a combined model of SaaS and joint research to provide efficient AI-assisted solutions for drug discovery enterprises.

Project 7: Biosomic Technologies: Validation of A Portable IVD device for Early Parkinson’s Disease Screening Using Neurosomal Biomarkers and Artificial Intelligence

Mr. Robert Jenkins Hamley, Chief Executive Officer, introduced that the device enables highly sensitive early screening of Parkinson’s disease using α-synuclein biomarkers in eCVs combined with AI clustering algorithms. The project is currently being validated through the EU multicenter clinical trial VαMPiRE. The company plans to advance registration simultaneously in China, the United States and Europe, and actively seeks Chinese partners to jointly promote product commercialization.

The overseas project roadshow attracted extensive attention from pharmaceutical innovators, investment institutions and research institutes worldwide. Following the session, numerous Chinese enterprises actively engaged with overseas roadshow projects via the CBIIC’s one-on-one partnering system to explore cooperation and investment opportunities.

Centered on cutting-edge topics in global pharmaceutical innovation, the overseas project roadshow provided an important platform for overseas enterprises to showcase technological achievements and exchange R&D concepts. By combining international innovation resources and industrial strengths, it enhanced connectivity within the pharmaceutical industry, accelerated the translation of scientific and technological achievements, and opened up broader prospects for global pharmaceutical innovation cooperation.